Please use this identifier to cite or link to this item:
Title: Homocysteine pre-treatment increases redox capacity in both endothelial and tumor cells.
Authors: Díaz-Santiago, Elena
Rodríguez-Caso, Luis
Cárdenas, Casimiro
Serrano, José J
Quesada, Ana R
Medina, Miguel Ángel
Keywords: Bovine aortic endothelial cells;Cysteine;Homocysteine;Homocysteine thiolactone;MDA-MB231 breast cancer cell;Redox
metadata.dc.subject.mesh: Antioxidants
Cell Line, Tumor
Endothelial Cells
Issue Date: 19-May-2016
Abstract: We studied the modulatory effects of homocysteine pre-treatment on the disulfide reduction capacity of tumor and endothelial cells. Human MDA-MB-231 breast carcinoma and bovine aorta endothelial cells were pre-treated for 1-24 hours with 0.5-5 mM homocysteine or homocysteine thiolactone. After washing to eliminate any rest of homocysteine or homocysteine thiolactone, cell redox capacity was determined by using a method for measuring disulfide reduction. Homocysteine pre-treatments for 1-4 hours at a concentration of 0.5-5 mM increase the disulfide reduction capacity of both tumor and endothelial cells. This effect cannot be fully mimicked by either cysteine or homocysteine thiolactone pre-treatments of tumor cells. Taken together, our data suggest that homocysteine can behave as an anti-oxidant agent by increasing the anti-oxidant capacity of tumor and endothelial cells.
metadata.dc.identifier.doi: 10.1080/13510002.2016.1183348
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.